58
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      C4B gene influences intestinal microbiota through complement activation in patients with paediatric-onset inflammatory bowel disease : C4B and paediatric inflammatory bowel disease

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p id="d3725270e363">Complement <i>C4</i> genes are linked to paediatric inflammatory bowel disease (PIBD), but the mechanisms have remained unclear. We examined the influence of <i>C4B</i> gene number on intestinal microbiota and <i>in‐vitro</i> serum complement activation by intestinal microbes in PIBD patients. Complement <i>C4A</i> and <i>C4B</i> gene numbers were determined by genomic reverse transcription–polymerase chain reaction (RT‐PCR) from 64 patients with PIBD (Crohn's disease or ulcerative colitis). The severity of the disease course was determined from faecal calprotectin levels. Intestinal microbiota was assessed using the HITChip microarray. Complement reactivity in patients was analysed by incubating their sera with <i>Yersinia pseudotuberculosis</i> and <i>Akkermansia muciniphila</i> and determining the levels of C3a and soluble terminal complement complex (SC5b‐9) using enzyme immunoassays. The microbiota diversity was wider in patients with no <i>C4B</i> genes than in those with one or two <i>C4B</i> genes, irrespective of intestinal inflammation. <i>C4B</i> and total <i>C4</i> gene numbers correlated positively with soluble terminal complement complex (TCC, SC5b‐9) levels when patient serum samples were stimulated with bacteria. Our results suggest that the <i>C4B</i> gene number associates positively with inflammation in patients with PIBD. Multiple copies of the <i>C4B</i> gene may thus aggravate the IBD‐associated dysbiosis through escalated complement reactivity towards the microbiota. </p>

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          The microbiome in inflammatory bowel disease: current status and the future ahead.

          Studies of the roles of microbial communities in the development of inflammatory bowel disease (IBD) have reached an important milestone. A decade of genome-wide association studies and other genetic analyses have linked IBD with loci that implicate an aberrant immune response to the intestinal microbiota. More recently, profiling studies of the intestinal microbiome have associated the pathogenesis of IBD with characteristic shifts in the composition of the intestinal microbiota, reinforcing the view that IBD results from altered interactions between intestinal microbes and the mucosal immune system. Enhanced technologies can increase our understanding of the interactions between the host and its resident microbiota and their respective roles in IBD from both a large-scale pathway view and at the metabolic level. We review important microbiome studies of patients with IBD and describe what we have learned about the mechanisms of intestinal microbiota dysfunction. We describe the recent progress in microbiome research from exploratory 16S-based studies, reporting associations of specific organisms with a disease, to more recent studies that have taken a more nuanced view, addressing the function of the microbiota by metagenomic and metabolomic methods. Finally, we propose study designs and methodologies for future investigations of the microbiome in patients with inflammatory gut and autoimmune diseases in general. Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inflammatory Bowel Disease in Children and Adolescents.

            The inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn disease, are chronic inflammatory disorders of the gastrointestinal tract most often diagnosed in adolescence and young adulthood, with a rising incidence in pediatric populations. These disorders are common enough in children that most pediatricians and other pediatric clinicians will encounter children with IBD in their general practice. Inflammatory bowel disease is caused by a dysregulated mucosal immune response to the intestinal microflora in genetically predisposed hosts. Although children can present with the classic symptoms of weight loss, abdominal pain, and bloody diarrhea, many present with nonclassic symptoms of isolated poor growth, anemia, or other extraintestinal manifestations. Once IBD is diagnosed, the goals of therapy consist of eliminating symptoms, normalizing quality of life, restoring growth, and preventing complications while minimizing the adverse effects of medications. Unique considerations when treating children and adolescents with IBD include attention to the effects of the disease on growth and development, bone health, and psychosocial functioning. The purpose of this review is to provide a contemporary overview of the epidemiologic features, pathogenesis, diagnosis, and management of IBD in children and adolescents.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults

              In this paper we present the in silico assessment of the diversity of variable regions of the small subunit ribosomal RNA (SSU rRNA) gene based on an ecosystem-specific curated database, describe a probe design procedure based on two hypervariable regions with minimal redundancy and test the potential of such probe design strategy for the design of a flexible microarray platform. This resulted in the development and application of a phylogenetic microarray for studying the human gastrointestinal microbiota – referred as the human intestinal tract chip (HITChip). Over 4800 dedicated tiling oligonucleotide probes were designed based on two hypervariable regions of the SSU rRNA gene of 1140 unique microbial phylotypes (< 98% identity) following analysis of over 16 000 human intestinal SSU rRNA sequences. These HITChip probes were hybridized to a diverse set of human intestinal samples and SSU rRNA clones to validate its fingerprinting and quantification potential. Excellent reproducibility (median Pearson's correlation of 0.99) was obtained following hybridization with T7 polymerase transcripts generated in vitro from SSU rRNA gene amplicons. A linear dose–response was observed with artificial mixtures of 40 different representative amplicons with relative abundances as low as 0.1% of total microbiota. Analysis of three consecutively collected faecal samples from ten individuals (five young and five elderly adults) revealed temporal dynamics and confirmed that the adult intestinal microbiota is an individual-specific and relatively stable ecosystem. Further analysis of the stable part allowed for the identification of a universal microbiota core at the approximate genus level (90% sequence similarity). This core consists of members of Actinobacteria, Bacteroidetes and Firmicutes. Used as a phylogenetic fingerprinting tool with the possibility for relative quantification, the HITChip has the potential to bridge the gaps in our knowledge in the quantitative and qualitative description of the human gastrointestinal microbiota composition.
                Bookmark

                Author and article information

                Journal
                Clinical & Experimental Immunology
                Clin Exp Immunol
                Wiley
                00099104
                December 2017
                December 2017
                September 25 2017
                : 190
                : 3
                : 394-405
                Affiliations
                [1 ]Immunobiology, Research Programs Unit; University of Helsinki; Helsinki Finland
                [2 ]Department of Bacteriology and Immunology; University of Helsinki; Helsinki Finland
                [3 ]Department of Medical and Clinical Genetics; University of Helsinki; Helsinki Finland
                [4 ]Transplantation Laboratory, Medicum; University of Helsinki; Helsinki Finland
                [5 ]Children's Hospital, University of Helsinki and Helsinki University Hospital; Helsinki Finland
                [6 ]Helsinki University Hospital Laboratory (HUSLAB); Helsinki Finland
                Article
                10.1111/cei.13040
                5680072
                28832994
                56a166ae-644d-4d43-b0fc-330c3f5ac4cb
                © 2017

                http://doi.wiley.com/10.1002/tdm_license_1.1

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                History

                Comments

                Comment on this article